TG Therapeutics, Inc. (TGTX) is a publicly traded Healthcare sector company. As of May 21, 2026, TGTX trades at $39.90 with a market cap of $6.04B and a P/E ratio of 12.32. TGTX moved +0.84% today. Year to date, TGTX is +32.98%; over the trailing twelve months it is +12.09%. Its 52-week range spans $21.16 to $46.48. Analyst consensus is neutral with an average price target of $44.25. Rallies surfaces TGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TG Therapeutics, Inc. (TGTX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. TGTX moved +0.84% today. Analyst consensus is neutral.
| Metric | Value |
|---|---|
| Price | $39.90 |
| Market Cap | $6.04B |
| P/E Ratio | 12.32 |
| EPS | $3.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $46.48 |
| 52-Week Low | $21.16 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $700.35M |
| Net Income | $461.90M |
| Gross Margin | 83.05% |
4 analysts cover TGTX: 0 strong buy, 2 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $44.25.